Senestech (NASDAQ:SNES) Major Shareholder Glenbrook Capital Management Purchases 5,685 Shares

Senestech, Inc. (NASDAQ:SNES) major shareholder Glenbrook Capital Management acquired 5,685 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was purchased at an average price of $1.82 per share, for a total transaction of $10,346.70. Following the acquisition, the insider directly owned 599,470 shares in the company, valued at $1,091,035.40. This represents a 0.96% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Glenbrook Capital Management also recently made the following trade(s):

• On Thursday, February 5th, Glenbrook Capital Management bought 2,884 shares of Senestech stock. The shares were acquired at an average cost of $1.77 per share, with a total value of $5,104.68.
• On Monday, February 2nd, Glenbrook Capital Management acquired 42,739 shares of Senestech stock. The stock was acquired at an average price of $1.98 per share, with a total value of $84,623.22.
• On Friday, January 30th, Glenbrook Capital Management bought 5,399 shares of Senestech stock. The shares were bought at an average price of $1.87 per share, for a total transaction of $10,096.13.

Senestech Trading Up 5.1%

NASDAQ SNES traded up $0.09 on Friday, reaching $1.87. 47,931 shares of the company were exchanged, compared to its average volume of 44,761. Senestech, Inc. has a fifty-two week low of $1.30 and a fifty-two week high of $6.24. The company has a current ratio of 15.75, a quick ratio of 14.73 and a debt-to-equity ratio of 0.01. The business’s fifty day moving average price is $2.29 and its 200 day moving average price is $3.57. The stock has a market capitalization of $9.76 million, a P/E ratio of -0.51 and a beta of 0.21.

Senestech (NASDAQ:SNES) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The firm had revenue of $0.69 million during the quarter, compared to analyst estimates of $0.73 million. Senestech had a negative net margin of 253.54% and a negative return on equity of 98.35%. Analysts forecast that Senestech, Inc. will post -10.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Senestech in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Hedge Funds Weigh In On Senestech

Several hedge funds and other institutional investors have recently made changes to their positions in SNES. Sabby Management LLC purchased a new position in Senestech in the third quarter worth approximately $313,000. Corsair Capital Management L.P. acquired a new position in Senestech in the second quarter valued at $255,000. Jane Street Group LLC purchased a new position in shares of Senestech during the second quarter worth about $161,000. Millennium Management LLC acquired a new stake in shares of Senestech in the 3rd quarter valued at about $126,000. Finally, Essex Investment Management Co. LLC purchased a new stake in Senestech in the third quarter valued at approximately $115,000. Hedge funds and other institutional investors own 5.19% of the company’s stock.

Senestech Company Profile

SenesTech, Inc (NASDAQ: SNES) is a biotechnology company specializing in non-lethal pest management solutions. The company’s core focus is the development and commercialization of fertility-based control methods for commensal rodents, providing an alternative to traditional rodenticides. By targeting the reproductive cycle of rats, SenesTech aims to reduce rodent populations over time without the use of toxic chemicals, offering a more sustainable approach for pest management professionals.

The company’s flagship product, ContraPest®, is an EPA-registered liquid bait that disrupts rodent reproduction.